BOSTON , Dec. 09, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP) today reported that the Company granted a new employee an option to purchase an aggregate of 65,000 shares of Ziopharm’s common stock effective November 21, 2019 .
– Membrane bound IL-15 (mbIL15) improves anti-tumor effect of TCR-modified T cells – – T cells expressing T-cell receptor (TCR) and mbIL15 can be infused day after gene transfer – BOSTON , Dec. 08, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or the “Company”) (Nasdaq:ZIOP), today
– Controlled IL-12 evaluated as monotherapy in an expanded number of patients reinforced favorable safety profile and initial data consistent with immune-mediated anti-tumor effects – – Controlled IL-12 can be combined with full dose of a PD-1 inhibitor; favorable safety profile and initial data
Presentation moved to 1:20 p.m. GMT (8:20 a.m. ET) on November 20, 2019 BOSTON , Nov. 18, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP) today announced that the Company’s presentation at the Jefferies 2019 London Healthcare Conference on November 20, 2019 , has been moved to 1:20
BOSTON , Nov. 11, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP) today announced that Laurence Cooper , M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to make a webcast presentation at the Jefferies 2019 London Healthcare Conference on November 20, 2019 , beginning
– Phase 2 trial of Sleeping Beauty TCR-T cell therapy for patients with solid tumors initiated at the National Cancer Institute (NCI) – – New agreement with MD Anderson Cancer Center to expand library of T-cell receptors (TCRs) targeting neoantigens; Enables new clinical trials – – Balance sheet
BOSTON , Oct. 30, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced that management will host a conference call and webcast on Thursday, November 7 , at 4:30 p.m. ET to provide a corporate update and discuss financial results for the third quarter ended September 30 ,
– Accelerates capability for TCR library expansion of T-cell receptors (TCRs) targeting neoatigens, including in hotspots – – Enables two new TCR-T clinical trials at MD Anderson leveraging the Sleeping Beauty non-viral gene transfer platform – – New lease for larger facility allows
– Industry veteran with 20+ years of global oncology drug development leadership – – Current CMO at Agios Pharmaceuticals ; Former VP of Product Development, Oncology at Genentech – BOSTON , Oct. 15, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP),
– Phase 1 clinical trial of CAR-T produced and infused in two days or less from gene transfer using Ziopharm’s Sleeping Beauty platform – – Rapid personalized manufacture of CD19-specific CAR-T for investigation in unaddressed patient population with relapsed leukemias and lymphoma after bone
